- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05469568
Hybrid Rehabilitation Approach Through Group Exercise and Telerehabilitation in Patients With Multiple Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the Czech population more than 20,000 people have been diagnosed with multiple sclerosis (MS), an autoimmune disease affecting a patient's central nervous system. This disease has a wide range of symptoms, with the most common ones being various motor disorders that negatively affect the locomotor function and patients' quality of life.
The positive effect of physical activity on human health is well known. This study aims to examine the effect of hybrid exercise program on people with MS. This exercise program includes ambulatory circuit training for twelve weeks followed by telerehabilitation. The aim of the study is to find out whether the exercise program will positively affect the movement skills of probands and improve their quality of life. Testing will done before the start of the exercise program, after twelve weeks and after 6 months. Movement skills will be tested by a set of movement tests called miniBEST test. For measuring quality of life the investigators will the SF-36 questionnaire will be used. Another goal will analyze participants' satisfaction with the intervention and adherence to regular physical activity.
The investigators anticipate that regular physical training combined with telerehabilitation will increase the motivation and effectiveness of independent training in people with MS leading to improvment of physical fitness, physical activity levels and quality of life.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Czech Republic
-
Brno, Czech Republic, Czechia, 625 00
- Michaela Sládečková
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18
- Confirmed diagnosis of Multiple Sclerosis based on McDonald criteria
- Minimal one month from last relapse
- Possibility to use smartphone or tablet because of using rehabilitation application
Exclusion Criteria:
- Illnesses which can limiting exercises activities (e.g. orthopedic, cardiology or other neurological diseases)
- Cognitive deficit which can limiting cooperation (fill a questionnaire, comply with movement task, using application)
- Relapse of diseases during study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Circuit training and telerehabilitation
The experimental group will participate in a 12-week rehabilitation program, including training once a week.
After the end of this outpatient program, participants will gain access to a mobile application in which participants will record all their physical activities.The mobile application will also include a library of exercises taught during the outpatient program so patients can practice them at home.
|
Patients participate in an ambulatory rehabilitation program (12 weeks) and then gain access to mobile application to record their movement activities.
This application will aslo inlude a library with exercise vidoes from the ambulatory program.
These videos should inspire patients to do the exercises at home.
|
|
Sham Comparator: Usual Care
Patients have usual care and usual information about importance of regular movement activities and recommendation of proper exercises.
Patients don't visit ambulatory rehabilitation program and they don't have access to an application
|
Patients have usual information about importance of regular movement activities and recommendation of proper exercises
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline Movement skills score at 12 weeks and 6 months
Time Frame: Baseline, 12 weeks, 6 months
|
Mini Balance Evaluation Systems Test (Mini BESTest) - 14-item scale for measure postural stability.
Maximum value is 28 points, minimum value is 0 point.
Higher scores mean a better outcome.
|
Baseline, 12 weeks, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline Depression score at 12 weeks and 6 months
Time Frame: Baseline, 12 weeks, 6 months
|
Beck's Depression Inventory (BDI) - 21-item, self-report rating.
Maximum value is 63 points, minimum value is 0 point.
Higher scores mean a worse outcome.
|
Baseline, 12 weeks, 6 months
|
|
Change from Baseline Walking skills score at 12 weeks and 6 months
Time Frame: Baseline, 12 weeks, 6 months
|
12-Item Multiple Sclerosis Walking Scale - self-report rating.
Maximum value is 60 points, minimum value is 12 point.
Higher scores mean a worse outcome.
|
Baseline, 12 weeks, 6 months
|
|
Exercise adherence
Time Frame: 6 months
|
Number of added movement activities in application.
Higher scores mean better adherence to exercise.
|
6 months
|
|
Change from Baseline Health related quality of life score at 12 weeks and 6 months
Time Frame: Baseline, 12 weeks, 6 months
|
Short Form Survey (SF-36) - 36-item.
Maximum value is 100 points, minimum value is 36 point.
Higher score mean a better outcome.
|
Baseline, 12 weeks, 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ladislav Batalik, Department of Rehabilitation, University Hospital Brno, Czech Republic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Hybrid rehabilitation approach
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; University of Copenhagen and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
Clinical Trials on Circuit training followed by telerehabilitation
-
Riphah International UniversityRecruitingParkinson DiseasePakistan
-
University Hospital of FerraraRecruiting
-
University Hospital of FerraraRecruiting
-
Hacettepe UniversityCompleted
-
Riphah International UniversityRecruiting
-
Clarkson UniversityTemple UniversityRecruitingVirtual Reality | Vestibular Training | Balance AssessmentUnited States
-
Clarkson UniversityActive, not recruitingVestibular DisorderUnited States
-
City University of New YorkIcahn School of Medicine at Mount Sinai; Bronx Veterans Medical Research Foundation...CompletedSpinal Cord Injuries | Tetraplegia/Tetraparesis | Paraplegia, Spinal | Paraplegia, SpasticUnited States
-
Riphah International UniversityCompleted
-
Colorado State UniversityUniversity of Colorado, Denver; National Institute of Diabetes and Digestive...RecruitingDepressive Disorder | Depression | Glucose Metabolism Disorders | Mood Disorders | Insulin Resistance | Hyperinsulinism | Metabolic Disease | Mental Disorder in AdolescenceUnited States